ERBB2 and breast cancer: Several randomized phase III clinical trials have clearly demonstrated that trastuzumab, a monoclonal antibody directed against the extracellular domain of HER2, meaningfully improves distant-free and overall survival when added to standard adjuvant chemotherapy for HER2-positive early breast cancer [11–20].